Molecular Screening Shared Resource

分子筛选共享资源为癌症中心成员提供最先进的高通量 shRNA和小分子文库的筛选能力，以识别基因和工具抑制剂 候选治疗靶点识别调节药物活性的药物样小分子， 治疗靶点在定义新的治疗模式方面有希望，特别是对于恶性肿瘤 类型，其中目前的临床实践是次优的。在2008年提交给Wistar癌症中心的报告中， 支持赠款，该资源的服务被纳入蛋白质表达和文库 共享资源。在超过100万美元的投资支持下，资源在年稳步增长。 仪器能力、服务范围和对广泛研究的科学影响 项目目前，该资源提供：1）基于生化、细胞和高含量的测定， 在384孔微量滴定板中的高通量筛选; 2）小分子文库的管理; 3）高通量 筛选小分子文库; 4）分析生物和化学数据集; 4） 在二级正交试验中表征新鉴定化合物的效力和选择性。 这些服务是通过配备机器人的中央实验室提供的， 以高密度微孔板格式排列的分子，以及用于高效分析的计算基础设施， 生物和化学数据集的解释和管理。资源由一个 经验丰富的常务董事和专门的实验室工作人员，在提供的所有服务交叉培训。这 允许及时的项目管理、质量保证和关键数据的传播/集成， 将基本的生物学观察转化为潜在的治疗策略。由于这种技术 扩展、用户群的增长以及服务的集成，资源现在作为独立的 癌症中心共享资源，并在操作上归类为II型资源，以反映高度 大多数服务的专业化、经常协作的性质。通过其在上一个项目期间的活动， 分子筛选资源使得能够解剖肿瘤发病的复杂信号通路 和进展，抗癌药物的验证，以及最终被 纳入早期临床试验。作为多学科研究合作的引擎， 该资源为所有三个癌症中心项目的关键出版物和赠款资金做出了贡献。

The Molecular Screening Shared Resource provides Cancer Center members with state-of-the-art high-throughput screening capabilities of shRNA and small molecule libraries to identify genes and tool inhibitors of candidate therapeutic targets. Identifying drug-like, small molecules that regulate the activity of therapeutic targets holds promise in defining new treatment paradigms, especially for recalcitrant tumor types, where current clinical practice is suboptimal. In the 2008 submission of the Wistar Cancer Center Support Grant, the services of this Resource were incorporated into the Protein Expression and Libraries Shared Resource. Backed by an investment of over $1 million, the Resource has grown steadily in instrumentation capabilities, range of services and scientific impact for a broad spectrum of research projects. Currently, the Resource offers: 1) biochemical-, cell-, and high-content based assays amenable to high-throughput screening in 384 well microtiter plates; 2) managing of libraries of small molecules; 3) high-throughput screening of small molecule libraries; 4) analysis of biological and chemistry datasets; 4) characterization of potency and selectivity of newly identified compounds in secondary, orthogonal assays. These services are provided through a centralized laboratory equipped with robotics, libraries of drug-like molecules arrayed in high-density microplate formats, and computational infrastructure for efficient analysis, interpretation, and management of biological and chemistry datasets. The Resource is operated by an experienced Managing Director and dedicated laboratory staff, cross-trained in all services offered. This allows for timely project management, quality assurance, and dissemination/integration of data critical for translation of basic biological observations into potential therapeutic strategies. As a result of this technical expansion, growth of user base, and integration of services, the Resource is now presented as a stand-alone Cancer Center Shared Resource, and operationally classified as a Type II Resource to reflect the highly specialized, frequently collaborative nature of most services. Through its activity over the last project period, the Molecular Screening Resource has enabled dissection of complex signaling pathways of tumor onset and progression, validation of anticancer agent(s), and proof of concept results that were ultimately incorporated into early phase clinical trials. As an engine for multidisciplinary research collaboration, the Resource has contributed to critical publications and grant funding across all three Cancer Center Programs.